Author: Paul Fletcher - Page 3

Impetigo and cellulitis are common bacterial skin infections with different causes, symptoms, and treatments. Learn how to tell them apart, which antibiotics work, and when to seek urgent care.

Pharmacogenomics reveals how your genes affect how your body processes drugs, reducing dangerous interactions and adverse reactions. Learn how genetic testing is changing prescribing practices and saving lives.

Dizziness and lightheadedness are common side effects of many medications, affecting 1 in 5 adults. Learn which drugs cause it, why it happens, and how to manage it safely without stopping treatment.

Generic drugs are just as safe and effective as brand-name medications but cost up to 85% less. Learn how they’re made, tested, and approved by the FDA through the ANDA process-step by step.

Menopause weight gain isn't about overeating-it's hormonal shifts, muscle loss, and a slower metabolism. Learn the science-backed strategies to fight belly fat and protect your long-term health.

Ordering medication from foreign websites may save money, but it puts your life at risk. Counterfeit drugs are widespread, often deadly, and nearly impossible to detect. Learn how to avoid them and stay safe.

NTI generics require stricter regulation than standard generics due to narrow margins between effective and toxic doses. This article explores how the FDA, EMA, Canada, and Japan differ in their approaches, what’s changing in 2025, and why prescribers must stay cautious.

Supportive care in cancer uses growth factors, antiemetics, and pain relief to manage treatment side effects, improve survival, and keep patients on track. Learn how these evidence-based tools work and why access remains unequal.

In 2025, the U.S. government expanded its drug shortage response with a new API stockpile program, but gaps in enforcement, funding, and economic incentives leave hospitals and patients vulnerable to ongoing shortages of critical medications.

Tentative FDA approval for generics means the drug is scientifically ready - but legal, manufacturing, or economic barriers often block its market launch. Here's why so many generics never reach patients.